MeiraGTx reacquires botaretigene sparoparvovec from J&J for USD 25m upfront

MeiraGTx (Nasdaq: MGTX) has acquired all interests in botaretigene sparoparvovec (bota-vec), an AAV-based gene therapy for X-linked retinitis pigmentosa, from Johnson & Johnson (NYSE: JNJ) via its Janssen Pharmaceuticals subsidiary. The asset purchase agreement covers all rights, title, and interest in bota-vec globally, with MeiraGTx paying USD 25 million upfront alongside a single combined regulatory and commercial milestone tied to US approval and US sales performance, plus a high double-digit royalty on global net sales commencing mid-2029.

The transaction is a reacquisition: MeiraGTx originally developed bota-vec in collaboration with University College London and Moorfields Eye Hospital before out-licensing the program to Janssen, and the company has continued to serve as the commercial manufacturer throughout. MeiraGTx will pay J&J USD 25 million at closing. The milestone quantum was not disclosed. The high double-digit royalty rate on global net sales — beginning mid-2029, roughly three years from signing — implies an anticipated commercial launch in 2027 followed by a ramp before royalty obligations trigger. No equity component was disclosed.

Deal context

Bota-vec is an adeno-associated virus (AAV) gene therapy described by the company as delivering a functional copy of the RPGR gene — encoding retinitis pigmentosa GTPase regulator, a ciliary protein critical for photoreceptor maintenance — to retinal cells in patients with XLRP. Published Phase I/II data in the American Journal of Ophthalmology confirmed the AAV5-based construct's safety and efficacy signals in RPGR-associated X-linked retinitis pigmentosa. XLRP is a rare X-linked recessive condition caused by mutations in the RPGR gene, characterized by early-onset progressive photoreceptor degeneration that typically advances to near-complete blindness by the third decade of life. No approved treatments exist. The company estimates more than 20,000 XLRP-RPGR patients in the US and EU combined.

The pivotal Phase III LUMEOS trial enrolled 95 patients and treated all bilaterally. The primary endpoint — a Visual Mobility Assessment measuring functional vision — did not reach statistical significance, though treated subjects were 2.4 times more likely to respond than untreated subjects. Secondary endpoints across three vision domains showed statistically significant and clinically meaningful improvements. Retinal sensitivity measures, including pointwise responders in the central 30 degrees and full visual field, each reached p=0.001. Low luminance visual acuity improved with statistical significance (p=0.003); 45% of treated patients gained more than 10 letters and 20% gained more than 15 letters. A multi-endpoint responder analysis showed 40% of treated patients improved in two or more endpoints across different vision domains versus 0% in the control group. The safety profile showed no new signals relative to Phase I/II, with an improved inflammatory profile. The US FDA has granted bota-vec Fast Track and Orphan Drug designations; EU regulators have granted Priority Medicines (PRIME), advanced therapy medicinal product (ATMP), and Orphan Drug designations.

MeiraGTx is already the commercial manufacturer of bota-vec, holding a GMP manufacturing license from the MHRA for its London facility and a commercial license for its QC facility in Shannon, Ireland. The company states it has completed process performance qualification and holds several hundred vials of product that can be used to treat patients immediately following approval. MeiraGTx intends to file a BLA with the US FDA and an MAA with the EMA, as well as a submission in Japan, as soon as possible, targeting a potential launch in 2027.

The reacquisition consolidates full vertical integration across the bota-vec program: MeiraGTx now holds IP ownership, regulatory responsibility, manufacturing, and commercial rights in a single entity. J&J retains only financial participation through the milestone and royalty structure, with no retained operational, development, or commercial control.

For MeiraGTx, bota-vec fits alongside AAV-hAQP1, its gene therapy for radiation-induced xerostomia, which is in the pivotal AQUAx 2 study with data expected in Q2 2027. The company has framed its near-term strategy around becoming a commercial-stage company with two products launching within two years, both targeting concentrated specialist markets with no existing treatment options. The inherited retinal disease community is served by approximately 40 to 50 centers of excellence in the EU, US, and Japan, which collectively manage roughly 80% of IRD patients; MeiraGTx states that 32 of those sites participated in the LUMEOS study.

MeiraGTx was founded in 2015 in collaboration with UCL and Moorfields Eye Hospital, institutions with deep inherited retinal disease expertise, and has maintained relationships with key opinion leaders across the IRD center network throughout the program's development under Janssen.

---

Spot something wrong? Report an issue with this article